CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

CG Oncology, Inc. reported net losses of $88.0 million and $48.6 million for the years ended December 31, 2024, and 2023, ...

Before Fadel Lawandy joined Chapman University, where he is the director of the C. Larry Hoag Center for Real Estate and Finance and director of the Janes Financial Center, he was a portfolio manager ...

The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, ...

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG ...

CG Oncology, Inc. ( ($CGON) ) has released its Q4 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors.

Tarsus Pharmaceuticals Inc. (Nasdaq: TARS), ranked No. 1 in the midsize category, has become a standout in OC’s biotech ...

CG Oncology (NASDAQ:CGON) may offer a combination of common stock, preferred stock, debt securities, and warrants through future offerings. Source: SEC filing More on CG Oncology, Inc. A First Take On ...

EDT CG Oncology (CGON) files automatic mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...